Highlights Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Delayed Nasdaq Other stock markets 01:03:45 2024-05-23 pm EDT			5-day change	1st Jan Change
3.66 ^USD	+1.10%		-29.62%	-60.00%

Mar. 21	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 05	Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	Dec. 20	CI
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	Nov. 16	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	23-06-27	CI
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	23-06-08	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
DERMATA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-02-21	AQ
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21	CI
Dermata Therapeutics Withdraws Registration Statement; Shares up Friday	22-12-30	MT
Dermata Therapeutics Withdraws Registration Statement	22-12-29	MT
Dermata Therapeutics, Inc. Announces Topline Results from Its Phase 2 Trial of Once-Weekly Topical Application of DMT310 for the Treatment of Moderate-To-Severe Rosacea	22-12-05	CI
DERMATA THERAPEUTICS, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-11-10	AQ
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
DERMATA THERAPEUTICS, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-08-15	AQ
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q2 Loss $-0.24	22-08-15	MT
DERMATA THERAPEUTICS, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-05-16	AQ
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q1 Loss $-0.33	22-05-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Highlights

Filters